Shanghai-based Fosun Pharma has cancelled the proposed acquisition of a 60% stake in OncoCare Cancer Centre, one of the largest private oncology practices in Singapore, according to its filing with the stock exchange.
Since the deal involved “a series of preliminary factors” that both parties could not fulfil before the due date on Oct 30, the two parties decided to terminate the transaction, the filing noted.
